Program
samelisant
Also written as “SUVN-G3031” and “Samelisant”.
Its studies are mostly in Cataplexy · Cognitive Dysfunction, led by Suven Life Sciences.
Furthest: phase 3, since Apr 13, 20263 company-led studies, 1 open or runningNext primary completion: Nov 19, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Suven Life Sciences | 31 open or running | phase 3since Apr 13, 2026 | Aug 18, 2016 | Nov 19, 2027phase 3 · NCT07540364 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 18, 2016First study: phase 1 study in Cognitive DysfunctionFirst studyNCT02881294 · 24 enrolled · United States
- Aug 26, 2019Phase 2 study in NarcolepsyNCT04072380 · 190 enrolled · United States, Canada
- Apr 13, 2026Phase 3 study in NarcolepsyPhase 3 reachedNCT07540364 · 240 planned · United States
Ahead
- Nov 19, 2027Primary completion: phase 3 study in NarcolepsyNCT07540364
TargetBeta
HRH3 →read by rule
“Histamine H3 receptor inverse agonist”ChEMBL 37, by rule
Other programs on HRH3
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| pitolisantrule | Harmony Biosciences | phase 3 | 8 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07540364Narcolepsy · United States | 3 | Recruiting | Nov 19, 2027 | 240 |
| NCT04072380Narcolepsy · United States, Canada | 2 | Completed | Jun 7, 2023 | 190 |
| NCT02881294Cognitive Dysfunction · United States | 1 | Completed | Sep 2017 | 24 |
How it is read
Names in the registry
- “SUVN-G3031”, 2 entries
- “Samelisant”, 1 entry
Conditions, from the studies’ own filings
- Cataplexy, 2 studies
- Cognitive Dysfunction, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.